Brief: Aclaris Therapeutics Sees Cash, Cash Equivalents And Marketable Securities As Of Sep. 30 Sufficient To Fund Operations Through End Of 2025
06/11/2023 12:09
Nov 6 (Reuters) - Aclaris Therapeutics Inc ACRS.O :
* ACLARIS THERAPEUTICS - SEES ITS CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES AS OF SEPT 30, SUFFICIENT TO FUND ITS
OPERATIONS THROUGH END OF 2025
Source text for Eikon: ID:nGNX7MH4BX
Further company coverage: ACRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations